{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:38:42Z","timestamp":1786700322412,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Clozapine treatment carries a risk of blood dyscrasias (BD) and requires indefinite monitoring in many jurisdictions, a major factor in its under-utilization. Although previous studies suggest BD risk is highest early in treatment, BD events have also been reported after many years. This study compares early vs late (&amp;gt;6\u00a0months) suspected blood dyscrasias (SBD) and examines rechallenge outcomes as a marker for clozapine-related causation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>A retrospective analysis of electronic health records from a large UK mental health service gathered demographic data, characteristics of SBD events, and outcomes of clozapine rechallenge, defined as reinitiation after SBD-related discontinuation. These variables were compared between early- and late-onset SBD groups using a 6-month treatment duration cutoff.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Of 130 patients with SBD leading to clozapine cessation, 59 had early-onset SBD. The incidence rate before 6\u00a0months was 5.54% per year vs 0.53% after 6\u00a0months, reflecting an incidence rate ratio of 10.4. Early-onset patients were younger, received lower clozapine doses, and had fewer concurrent antipsychotics. Of 81 rechallenge attempts, 71 (87.7%) were successful, with a mean follow-up of 2.5\u00a0years. No significant differences in characteristics or rechallenge outcomes were found between the early- and late-onset groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Though less frequent, late-onset SBD shares similar characteristics with early-onset SBD and has a comparable risk of recurrence on clozapine rechallenge. Vast majority of clozapine rechallenges are successful, including early-onset BD, suggesting they are not clozapine-induced. However, clozapine-induced BD, defined by recurrence upon rechallenge, may rarely occur even after years of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbaf148","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T11:42:49Z","timestamp":1754134969000},"source":"Crossref","is-referenced-by-count":0,"title":["Late-Onset Neutropenia in Clozapine Users: Unrelated or Drug-Induced? A Case-Registry Analysis of Incidence, Characteristics, and Rechallenge Attempts"],"prefix":"10.1093","volume":"52","author":[{"given":"Aviv","family":"Segev","sequence":"first","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London , London , SE5 8AF,","place":["United Kingdom"]},{"name":"NIHR Biomedical Research Centre for Mental Health South London and Maudsley NHS , London , SE5 8AF,","place":["United Kingdom"]},{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv , 69978,","place":["Israel"]},{"name":"Shalvata Mental Health Centre, Hod Hasharon , 4534708,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risha","family":"Govind","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London , London , SE5 8AF,","place":["United Kingdom"]},{"name":"NIHR Biomedical Research Centre for Mental Health South London and Maudsley NHS , London , SE5 8AF,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-4017","authenticated-orcid":false,"given":"Ebenezer","family":"Oloyede","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South London and Maudsley NHS Foundation Trust , London , SE5 8AZ,","place":["United Kingdom"]},{"name":"Department of Psychiatry, University of Oxford , Oxford , OX3 7JX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Casetta","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London , London , SE5 8AF,","place":["United Kingdom"]},{"name":"National Psychosis Service, South London and Maudsley NHS Foundation Trust , London , BR3 3BX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pritchard","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre for Mental Health South London and Maudsley NHS , London , SE5 8AF,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Jewell","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre for Mental Health South London and Maudsley NHS , London , SE5 8AF,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Broadbent","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre for Mental Health South London and Maudsley NHS , London , SE5 8AF,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3470-0413","authenticated-orcid":false,"given":"Harsimran Kaur","family":"Makan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South London and Maudsley NHS Foundation Trust , London , SE5 8AZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacCabe","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London , London , SE5 8AF,","place":["United Kingdom"]},{"name":"NIHR Biomedical Research Centre for Mental Health South London and Maudsley NHS , London , SE5 8AF,","place":["United Kingdom"]},{"name":"National Psychosis Service, South London and Maudsley NHS Foundation Trust , London , BR3 3BX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2026081405132757600_ref1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: Systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br J Psychiatry"},{"key":"2026081405132757600_ref2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"2026081405132757600_ref3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","article-title":"Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia","volume":"173","author":"Stroup","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2026081405132757600_ref4","first-page":"15","article-title":"Suicide in schizophrenia: risk factors and clozapine treatment","volume":"59 Suppl 3","author":"Meltzer","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2026081405132757600_ref5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","volume":"174","author":"Wimberley","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2026081405132757600_ref6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/fnl.14.23","article-title":"Making clozapine safer: current perspectives on improving its tolerability","volume":"9","author":"Nair","year":"2014","journal-title":"Future Neurol."},{"key":"2026081405132757600_ref7","first-page":"449","article-title":"There is room for improvement: the rate of clozapine use AMONG patients with schizophrenia IN ISRAEL","volume":"158","author":"Krivoy","year":"2019","journal-title":"Harefuah."},{"key":"2026081405132757600_ref8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/acps.13280","article-title":"An evaluation of the variation and underuse of clozapine in the United Kingdom","volume":"143","author":"Whiskey","year":"2021","journal-title":"Acta Psychiatr Scand."},{"key":"2026081405132757600_ref9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3109\/08039488.2016.1155234","article-title":"Clozapine treatment and discontinuation in Iceland: a national longitudinal study using electronic patient records","volume":"70","author":"Ingimarsson","year":"2016","journal-title":"Nord J Psychiatry"},{"key":"2026081405132757600_ref10","doi-asserted-by":"publisher","first-page":"e909","DOI":"10.4088\/JCP.15r10085","article-title":"Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations","volume":"77","author":"Manu","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"2026081405132757600_ref11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","article-title":"Reasons for discontinuing clozapine: a cohort study of patients commencing treatment","volume":"174","author":"Legge","year":"2016","journal-title":"Schizophr Res"},{"key":"2026081405132757600_ref12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"Nielsen","year":"2016","journal-title":"CNS Drugs"},{"key":"2026081405132757600_ref13","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1017\/S204579602200066X","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2026081405132757600_ref14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/acps.12193","article-title":"Practitioner attitudes to clozapine initiation","volume":"130","author":"Gee","year":"2014","journal-title":"Acta Psychiatr Scand."},{"key":"2026081405132757600_ref15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull."},{"key":"2026081405132757600_ref16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14740338.2016.1191468","article-title":"Clozapine\u2019s critical role in treatment resistant schizophrenia: ensuring both safety and use","volume":"15","author":"Remington","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"2026081405132757600_ref17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr Scand."},{"key":"2026081405132757600_ref18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/YIC.0000000000000270","article-title":"Clozapine-associated neutropenia in Latin America: incidence report of 5380 Chilean users","volume":"34","author":"Mena","year":"2019","journal-title":"Int Clin Psychopharmacol."},{"key":"2026081405132757600_ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"16","author":"Ingimarsson","year":"2016","journal-title":"BMC Psychiatry."},{"key":"2026081405132757600_ref20","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.104","article-title":"Identifying clinically relevant agranulocytosis in people registered on the UK clozapine central non-rechallenge database: retrospective cohort study","volume":"225","author":"Oloyede","year":"2024","journal-title":"Br J Psychiatry."},{"key":"2026081405132757600_ref21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/02698811241262767","article-title":"Severe neutropenia unrelated to clozapine in patients receiving clozapine","volume":"38","author":"Taylor","year":"2024","journal-title":"J Psychopharmacol."},{"key":"2026081405132757600_ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l484","article-title":"The art of clozapine therapy and \u201cclozaphobia\u201d","volume":"364","author":"Pandarakalam","year":"2019","journal-title":"BMJ."},{"key":"2026081405132757600_ref23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1192\/bjp.188.3.255","article-title":"Rechallenge with clozapine following leucopenia or neutropenia during previous therapy","volume":"188","author":"Dunk","year":"2006","journal-title":"Br J Psychiatry."},{"key":"2026081405132757600_ref24","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1097\/MJT.0000000000000715","article-title":"Clozapine Rechallenge after major adverse effects: clinical guidelines based on 259 cases","volume":"25","author":"Manu","year":"2018","journal-title":"Am J Ther."},{"key":"2026081405132757600_ref25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/JCP.0000000000001371","article-title":"Continuation of treatment with clozapine after an episode of neutropenia","volume":"41","author":"Tirupati","year":"2021","journal-title":"J Clin Psychopharmacol."},{"key":"2026081405132757600_ref26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/JCP.0000000000000512","article-title":"Clozapine rechallenge after neutropenia or leucopenia","volume":"36","author":"Prokopez","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"2026081405132757600_ref27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00023210-200721010-00003","article-title":"Restarting clozapine after neutropenia evaluating the possibilities and practicalities","volume":"21","author":"Whiskey","year":"2007","journal-title":"CNS Drugs."},{"key":"2026081405132757600_ref28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","article-title":"Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring","volume":"25","author":"Wici\u0144ski","year":"2018","journal-title":"Curr Opin Hematol."},{"key":"2026081405132757600_ref29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/all.13765","article-title":"Immune pathomechanism and classification of drug hypersensitivity","volume":"74","author":"Pichler","year":"2019","journal-title":"Allergy."},{"key":"2026081405132757600_ref30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/pgs-2018-0188","article-title":"Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective","volume":"20","author":"Legge","year":"2019","journal-title":"Pharmacogenomics."},{"key":"2026081405132757600_ref31","doi-asserted-by":"publisher","first-page":"e1410","DOI":"10.4088\/JCP.14m09326","article-title":"Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis","volume":"76","author":"Meyer","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2026081405132757600_ref32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","article-title":"Sodium valproate and clozapine induced neutropenia: a case control study using register data","volume":"195","author":"Malik","year":"2018","journal-title":"Schizophr Res."},{"key":"2026081405132757600_ref33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br J Psychiatry."},{"key":"2026081405132757600_ref34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/JCP.0000000000000467","article-title":"Successful use of single doses of granulocyte-Colony stimulating factor (G-CSF) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report","volume":"36","author":"Comacchio","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"2026081405132757600_ref35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.11m07244","article-title":"Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted","volume":"73","author":"Lahdelma","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"2026081405132757600_ref36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1176\/appi.ajp.2012.12081036","article-title":"White blood cell monitoring during long-term clozapine treatment","volume":"170","author":"Cohen","year":"2013","journal-title":"Am J Psychiatry."},{"key":"2026081405132757600_ref37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case\u2013control study in Finland","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry."},{"key":"2026081405132757600_ref38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.schres.2023.09.024","article-title":"Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed?","volume":"268","author":"Schulte","year":"2024","journal-title":"Schizophr Res."},{"key":"2026081405132757600_ref39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.2023.44","article-title":"Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study","volume":"223","author":"Oloyede","year":"2023","journal-title":"Br J Psychiatry."},{"key":"2026081405132757600_ref40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","article-title":"Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study","volume":"11","author":"Northwood","year":"2024","journal-title":"Lancet Psychiatry."},{"key":"2026081405132757600_ref41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-51","article-title":"The South London and Maudsley NHS Foundation Trust biomedical research Centre (SLAM BRC) case register: development and descriptive data","volume":"9","author":"Stewart","year":"2009","journal-title":"BMC Psychiatry."},{"key":"2026081405132757600_ref42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/schbul\/sbab006","article-title":"There is life after the UK clozapine central non-rechallenge database","volume":"47","author":"Oloyede","year":"2021","journal-title":"Schizophr Bull."},{"key":"2026081405132757600_ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06022-5","article-title":"Developing a validated methodology for identifying clozapine treatment periods in electronic health records","volume":"24","author":"Segev","year":"2024","journal-title":"BMC Psychiatry."},{"key":"2026081405132757600_ref44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood.2020008600","article-title":"When non-whiteness becomes a condition","volume":"137","author":"Merz","year":"2021","journal-title":"Blood."},{"key":"2026081405132757600_ref45","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/ph15070817","article-title":"Adverse drug reactions in relation to clozapine plasma levels: a systematic review","volume":"15","author":"Skokou","year":"2022","journal-title":"Pharmaceuticals."},{"key":"2026081405132757600_ref46","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"Myles","year":"2019","journal-title":"Aust N Z J Psychiatry."},{"key":"2026081405132757600_ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04659-2","article-title":"Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Psychiatry."},{"key":"2026081405132757600_ref48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/15622970310029918","article-title":"Morning pseudoneutropenia during clozapine treatment","volume":"4","author":"Esposito","year":"2009","journal-title":"World J Biol Psychiatry."},{"key":"2026081405132757600_ref49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1176\/appi.focus.20200029","article-title":"Never say never: successful clozapine Rechallenge after multiple episodes of neutropenia","volume":"19","author":"Shuman","year":"2021","journal-title":"Focus (Am Psychiatr Publ)."},{"key":"2026081405132757600_ref50","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211015070","article-title":"Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital","volume":"11","author":"Silva","year":"2021","journal-title":"Ther Adv Psychopharmacol."},{"key":"2026081405132757600_ref51","first-page":"162","article-title":"Positive allergological tests may turn negative with no further exposure to the specific allergen: a long-term, prospective, follow-up study in patients allergic to penicillin","volume":"6","author":"Patriarca","year":"1996","journal-title":"J Investig Allergol Clin Immunol."},{"key":"2026081405132757600_ref52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaci.2005.10.030","article-title":"Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions","volume":"117","author":"Beeler","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"2026081405132757600_ref53","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S2215-0366(22)00188-2","article-title":"Relaxation of the criteria for entry to the UK clozapine central non-Rechallenge database: a modelling study","volume":"9","author":"Oloyede","year":"2022","journal-title":"Lancet Psychiatry."},{"key":"2026081405132757600_ref54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.schres.2024.08.018","article-title":"The timing and severity of clozapine-associated neutropenia in the US: is the risk overstated?","volume":"272","author":"Brandt","year":"2024","journal-title":"Schizophr Res."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/4\/sbaf148\/64137723\/sbaf148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/4\/sbaf148\/64137723\/sbaf148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:14:39Z","timestamp":1786698879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbaf148\/8241313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaf148","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,8,26]]},"article-number":"sbaf148"}}